ME01456B - Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola - Google Patents

Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola

Info

Publication number
ME01456B
ME01456B MEP-2012-95A MEP9512A ME01456B ME 01456 B ME01456 B ME 01456B ME P9512 A MEP9512 A ME P9512A ME 01456 B ME01456 B ME 01456B
Authority
ME
Montenegro
Prior art keywords
alpha
beta
naphthalenyl
dimethylamino
methoxy
Prior art date
Application number
MEP-2012-95A
Other languages
English (en)
Unknown language (me)
Inventor
Pharmaceutica N V Janssen
Johann Winkler
Remoortere Peter Jozef Maria Van
Anne Faure
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01456(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ME01456B publication Critical patent/ME01456B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
MEP-2012-95A 2006-12-05 2007-12-03 Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola ME01456B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
EP07847697A EP2086940B1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
ME01456B true ME01456B (me) 2014-04-20

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2012-95A ME01456B (me) 2006-12-05 2007-12-03 Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola

Country Status (34)

Country Link
US (1) US8546428B2 (OSRAM)
EP (1) EP2086940B1 (OSRAM)
JP (2) JP2010511663A (OSRAM)
KR (1) KR101514700B1 (OSRAM)
CN (2) CN101547904A (OSRAM)
AP (1) AP2498A (OSRAM)
AR (1) AR064149A1 (OSRAM)
AU (1) AU2007328945B2 (OSRAM)
BR (1) BRPI0719693A2 (OSRAM)
CA (1) CA2668512C (OSRAM)
CL (1) CL2007003472A1 (OSRAM)
CY (1) CY1113594T1 (OSRAM)
DK (1) DK2086940T3 (OSRAM)
EA (1) EA017091B9 (OSRAM)
ES (1) ES2387923T3 (OSRAM)
HK (1) HK1214513A1 (OSRAM)
HR (1) HRP20120639T1 (OSRAM)
IL (1) IL199077A (OSRAM)
JO (1) JO2973B1 (OSRAM)
ME (1) ME01456B (OSRAM)
MX (1) MX2009005909A (OSRAM)
MY (1) MY148844A (OSRAM)
NO (1) NO342773B1 (OSRAM)
NZ (1) NZ576485A (OSRAM)
PE (1) PE20081350A1 (OSRAM)
PL (1) PL2086940T3 (OSRAM)
PT (1) PT2086940E (OSRAM)
RS (1) RS52408B (OSRAM)
SI (1) SI2086940T1 (OSRAM)
TW (1) TWI417098B (OSRAM)
UA (1) UA97813C2 (OSRAM)
UY (1) UY30762A1 (OSRAM)
WO (1) WO2008068231A1 (OSRAM)
ZA (1) ZA200903907B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
AU2016212116B2 (en) * 2015-01-27 2021-07-15 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
PT3971177T (pt) * 2016-07-20 2024-07-30 Novartis Ag Derivados de aminopiridina e a sua utilização como inibidores seletivos de alk-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
EP3651736B1 (en) 2017-07-14 2021-06-23 Janssen Pharmaceutica NV Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
US20220062319A1 (en) 2019-01-09 2022-03-03 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2001503411A (ja) * 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
RS52431B (sr) 2002-07-25 2013-02-28 Janssen Pharmaceutica N.V. Derivati hinolina i njihova upotreba kao mikobakterijskih inhibitora
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза

Also Published As

Publication number Publication date
RS52408B (sr) 2013-02-28
CA2668512A1 (en) 2008-06-12
ZA200903907B (en) 2013-08-28
CN101547904A (zh) 2009-09-30
HRP20120639T1 (hr) 2012-08-31
AR064149A1 (es) 2009-03-18
JO2973B1 (en) 2016-03-15
ES2387923T3 (es) 2012-10-04
HK1214513A1 (zh) 2016-07-29
NO20092535L (no) 2009-08-06
US8546428B2 (en) 2013-10-01
CN105012303A (zh) 2015-11-04
US20100028428A1 (en) 2010-02-04
IL199077A (en) 2016-09-29
CY1113594T1 (el) 2016-06-22
CA2668512C (en) 2015-03-24
PL2086940T3 (pl) 2012-10-31
NZ576485A (en) 2012-01-12
EA200970532A1 (ru) 2009-10-30
MY148844A (en) 2013-06-14
PT2086940E (pt) 2012-08-09
KR101514700B1 (ko) 2015-04-24
CL2007003472A1 (es) 2008-08-22
TWI417098B (zh) 2013-12-01
AP2498A (en) 2012-10-19
SI2086940T1 (sl) 2012-09-28
EA017091B1 (ru) 2012-09-28
PE20081350A1 (es) 2008-09-18
EP2086940A1 (en) 2009-08-12
AU2007328945B2 (en) 2014-04-03
TW200838527A (en) 2008-10-01
KR20090087020A (ko) 2009-08-14
BRPI0719693A2 (pt) 2013-12-24
JP2010511663A (ja) 2010-04-15
DK2086940T3 (da) 2012-08-20
EP2086940B1 (en) 2012-05-16
UA97813C2 (uk) 2012-03-26
AP2009004870A0 (en) 2009-06-30
JP5894239B2 (ja) 2016-03-23
AU2007328945A1 (en) 2008-06-12
UY30762A1 (es) 2008-07-03
EA017091B9 (ru) 2014-10-30
WO2008068231A1 (en) 2008-06-12
NO342773B1 (no) 2018-08-06
JP2015028049A (ja) 2015-02-12
MX2009005909A (es) 2009-06-16

Similar Documents

Publication Publication Date Title
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
GEP20146125B (en) Aminopyrimidines as syk inhibitors
DK2150530T3 (da) Substituerede sulfonamid-derivater
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
DE602007005387D1 (de) Ptors
AR066936A1 (es) 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
TW200730498A (en) Compounds
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
EA200901205A1 (ru) Фармацевтическая композиция, содержащая соль розиглитазона